Form 4: Adial Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
James W. Newman, Jr., a director of Adial Pharmaceuticals, Inc., acquired stock options on March 25, 2024.
Summary
- On March 25, 2024, James W. Newman, Jr., a director of Adial Pharmaceuticals, Inc., acquired stock options.
- The options grant the right to buy 12,000 shares of common stock at an exercise price of $1.35.
- The options vest pro rata on a monthly basis over 36 months, starting April 25, 2024.
- The options expire on March 24, 2034.
- Following the transaction, Newman directly owns 12,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Director acquired stock options. |
| 04/25/2024 | Vesting start date: Options vest pro rata monthly over 36 months. |
| 03/24/2034 | Expiration date: Stock options expire. |
| 03/27/2024 | Date of Form 4 filing. |
Keywords
stock options, director, acquisition, ADIL, Adial Pharmaceuticals, Form 4, Newman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.